Fall-risk-increasing drugs and falls requiring health care among older people with intellectual disability in comparison with the general population: A register study

Anna Axmon1,2*, Magnus Sandberg2, Gerd Ahlström2, Patrik Midlöv3

1 Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden, 2 Department of Health Sciences, Lund University, Lund, Sweden, 3 Center for Primary Health Care Research, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden

* anna.axmon@med.lu.se

Abstract

Background
Falls are the most common cause of injury for older people in the general population as well as among those with intellectual disability. There are many risk factors for falls, including a range of drugs which are considered to be fall-risk-increasing (FRIDs). The aim of the present study was to describe prescription patterns of FRIDs in itself as well as in relation to falls requiring health care among older people with intellectual disability and their age-peers in the general population. Moreover, to investigate possible differences between the two groups.

Methods
A cohort of people with intellectual disability and a referent cohort, one-to-one-matched by sex and year of birth, were established. Each cohort comprised 7936 people aged 55+ years at the end of 2012. Register data were collected for 2006–2012 on prescription of anti-depressants, anxiolytics, hypnotics and sedatives, opioids, and antipsychotics, as well as for fall-related health care contacts. Analyses were performed on yearly data, using repeated measures models.

Results
People with intellectual disability were more likely to be prescribed at least one FRID (Relative Risk [RR] 2.31). The increase was highest for antipsychotics (RR 25.0), followed by anxiolytics (RR 4.18), antidepressants (RR 2.72), and hypnotics and sedatives (RR 1.42). For opioids, however, a lower prevalence (RR 0.74) was found. In both cohorts, those with prescription of at least one FRID were more likely to have a fall-related injury that required health care. The increased risk was higher in the referent cohort (RR 3.98) than among people with intellectual disability (RR 2.27), although people with intellectual disability and prescription still had a higher risk of falls than those with prescription in the referent cohort (RR 1.27). A similar pattern was found for all drug groups, except for opioids, where prescription carried the same risk of having a fall-related injury that required health care in both cohorts. 
Conclusions

With or without prescription of FRIDs, older people with ID have a higher risk of falls requiring health care than their age-peers in the general population. It is important to be aware of this when prescribing drugs that further increase the risk of falls.

Introduction

Falls are the most common cause of injury in the general older population [1–3] as well as among people with intellectual disability (ID) [3–6]. In comparison with the general population, people with ID are at increased risk of falls, fall-related fractures, and other fall-related injuries [4, 6–10], and the association between falls and injuries is stronger [3]. There are several possible explanations for this discrepancy, many of which relate to personal and health factors among people with ID, such as epilepsy or other seizure disorders [4, 5, 11], behavioral problems [5], and urinary incontinence [4].

In the general population, a range of drugs have been identified as fall-risk-increasing drugs (FRIDs), e.g., antidepressants, anxiolytics, hypnotics and sedatives, and antipsychotics [12–17]. All of these drugs are commonly prescribed to people with ID [18, 19]. Thus, a higher use of FRIDs could partly explain the increased risk of falls and fall-related injuries among people with ID. To date, no results regarding differences in prescription or use of FRIDs as a potential pathway to differences in falls are available in the scientific literature, although a conference presentation by Foran et al [20] indicates a possible association between drug use and risk of falling among people with ID.

Apart from prescription of FRIDs, a variety of medical conditions which are common among people with ID could explain the discrepancy in falls and fall-related injuries. These include epilepsy [21, 22], psychosis [23, 24], depression [25, 26], heart disease and cardiovascular disorders [10, 25], pain [10, 27], dementia and other cognitive impairments [25, 28], Parkinson disease [25, 29], visual impairments [10, 25], and diabetes [25, 30]. Differences in prevalence of such medical conditions should be taken into consideration when assessing the effect of FRIDs on risk of falls among people with ID in comparison with the general population.

The aim of the present study was to describe prescription patterns of FRIDs in itself as well as in relation to falls requiring health care among older people with ID and their age-peers in the general population. We also investigated possible differences between the two groups.

Materials and methods

Data sources

This is a register-based study and uses four Swedish national registers. The registers and their use in the study have been described in detail previously [31]. Briefly, the LSS register, which contains information on support and services provided to people with ID and/or autism spectrum disorder, was used to identify a cohort of people with ID (the ID cohort) aged 55+ years and alive at the end of 2012 (n = 7936). The Total Population Register, in which life events of the Swedish population are collected, was used to establish a reference cohort from the general population (the gPop cohort), one-to-one matched on birth year and sex. Data regarding prescriptions of FRIDs were collected from the Swedish Prescribed Drugs Register for the period 2006–2012. This register contains information on all dispensed prescriptions in Sweden based...
on the Anatomical Therapeutic Chemical (ATC) classification system [32]. The ATC system consists of five levels, where the fifth level identifies the chemical substance. The ATC classification system also includes Defined Daily Dose (DDD) for many drugs, where the DDD is the average adult dose used for the main indication of the medicine. Finally, the National Patient Register, which contains information on inpatient care episodes and outpatient specialist visits, with diagnoses recorded according to ICD-10 (International Statistical Classification of Diseases and Related Health Problems 10th Revision), was used to identify fall-related health care contacts during 2006–2012. These were used as a proxy for falls.

Fall-risk-increasing drugs and health care contacts due to falls

In 2010, the Swedish National Board of Health and Welfare published a report listing drugs that may need extra attention among older people [1]. One group of such drugs were those that may increase the risk of falls. This group included drugs that may cause orthostatic hypotension (ATC-codes C01D, C02, C03, C07, C08, C09, G04CA, N04B, N05A excluding N05AN, and N06A), opioids (N02A), antipsychotics (N05A excluding N05AN), anxiolytics (N05B), hypnotics and sedatives (N05C), and antidepressants (N06A). In the present study, we included those drugs acting on the nervous system (ATC-code N), i.e. antidepressants (N06A), antipsychotics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), and opioids (N02A). We compared the ID cohort with the gPop cohort with respect to a) having at least one prescription of each drug during each year, b) number of years with prescription, and c) individual average DDD per drug during years with prescription. These analyses were performed for the whole cohorts, as well as stratified by sex.

Through the National Patient Register, we identified all health care contacts that were registered as due to falls (diagnostic codes W00-W19 in ICD-10). We will henceforth refer to these as “fall”. We compared those with at least one prescription of each FRID during each year in the ID cohort to those with at least one prescription of that FRID in the gPop cohort with respect to falls during that year.

Potential confounders

In order to evaluate whether potential differences in falls between the ID and gPop cohorts could–at least partly–be explained by discrepancies in fall-risk-increasing conditions, we collected information on such conditions from the National Patient Register. Conditions included were epilepsy (G40-G41 in ICD-10, n = 1300 in the ID cohort and n = 81 in the gPop cohort), psychosis (F20-F29; n = 426 and n = 43), depression (F32-F33; n = 413 and n = 312), dysrhythmia (I44-I49; n = 362 and n = 555) and heart failure (I50; n = 359 and n = 236), pain (M25.5, M54.5, M54.6, M79.6, R07, R10, R30, and R52; n = 1730 and n = 2275), dementia and other cognitive impairments (F00-F05; n = 94 and n = 53), Parkinson disease (G20-G22; n = 71 and n = 28), visual impairments (H0-H4; n = 1525 and n = 1110), and diabetes (E10-E14; n = 801 and n = 652).

Statistics

Analyses of dichotomous outcomes (e.g. having at least one prescription) were performed using generalized linear models (GLM) with a Poisson distribution and log link, thus estimating relative risks (RRs) with 95% confidence intervals (CIs). The two cohorts were compared with respect to prescription of different groups of FRIDs. Moreover, among those with prescription, cohort comparisons were made with respect to risk of falls. Both these analyses were performed using yearly observations, using calendar year to indicate repeated measures.
To investigate whether potential differences in fall risk was a reflection of overall differences in fall-risk between people with ID and the general population, we evaluated the interaction effect between having prescription of FRIDs and cohort affiliation on having a fall. This was done by adding an interaction term to the GLM.

In the analyses of cohort differences in risk of prescription on falls, potential confounding of fall-risk-increasing disorders was assessed by entering each diagnosis, one by one, into the model. Confounding was considered present if the RR for falls changed at least 10% when the diagnosis was included.

P-p-plots revealed that although the original values of individual average DDD were skewed, ln-transformed values were normally distributed. Thus, analyses were performed using Analysis of Variance (ANOVA) on ln-transformed values. As data regarding number of years with prescriptions were skewed both in their original form and after Ln-transformation, comparisons were made using the Mann-Whitney U-test.

A two-tailed p-value of 0.05 was considered statistically significant. All statistical analyses were performed in IBM SPSS Statistics version 23.

**Ethics**

Approval was obtained from the Regional Ethical Review Board in Lund (reg no 2013/15). The National Board of Health and Welfare performed a separate secrecy review in 2014 before providing access to the data. All analyses were performed using anonymized datasets.

Data in the present study are based on anonymized information provided by two official government agencies: The National Board of Health and Welfare and Statistics Sweden. These authorities provide anonymized information for research purposes to individual researchers once the study has been vetted and approved by the Regional Ethical Review Board according to Swedish ethical review regulations. Due to the requirement of anonymized data, each individual could not be asked for consent to participate; active refusal of participation was instead applied. This was done by publishing information about the planned study in the Swedish national newspaper “Dagens Nyheter” and in UNIK, the magazine of The Swedish National Association for People with Intellectual Disability (FUB). The target audience for the UNIK magazine is mainly members (people with ID) and their families. Two versions of the advertisement were written, whereof one was an easy-to-read text. The advertisement presented the study and contained information on how to contact the research manager (GA) by phone, email or mail in order to opt out of the study. The research manager was then responsible for contacting the two national government agencies so that those who opted out were excluded before the authorities provided any data to the research manager.

**Results**

Of the 7936 individuals included in each cohort, 3609 (45%) were women and 4327 (55%) were men. The age at the start of the study period, i.e. in 2006, ranged between 49 and 90 years, with a median age of 57 years. In the ID cohort, 5794 people (73%) had at least one FRID prescribed during the study period, and 2173 (27%) had at least one fall. The corresponding numbers in the gPop cohort were 4193 (53%) for prescription of FRIDs and 1139 (14%) for falls.

**Drug prescriptions**

Using yearly data, people in the ID cohort were more likely than those in the gPop cohort to be prescribed at least one FRID (Table 1). The higher prevalence was found for all investigated FRIDs except opioids, for which the opposite prescription pattern was found. The largest
An increase was found for antipsychotics, followed by anxiolytics, antidepressants, and hypnotics and sedatives. When stratified by sex, a similar pattern emerged as when analyzing the whole cohorts. However, the higher prevalence associated with ID was consistently higher among men than among women.

Among those with at least one prescription in the ID cohort, prescription during the entire study period was common, with 60% having at least one prescription of FRIDs during each year compared to 19% in the gPop cohort. This resulted in a higher median number of years with prescription in the ID cohort for all FRIDs with the exception of opioids (Table 2). The results were consistent when stratified by sex.

Among those with at least one prescription of each respective FRID, people in the ID cohort were prescribed higher annual doses (measured as DDDs) for each year with a prescription than people in the gPop cohort (Table 2). Again, the only exception was opioids.

### Prescriptions vs falls

Using yearly data, those with prescriptions of any FRID in both the ID and gPop cohort were more likely to have a fall (Table 3). With the exception of antipsychotics, an increased risk of falls was associated with ID cohort affiliation for all FRIDs. A possible interaction between cohort affiliation and having at least one prescription of FRIDs during the study period was found for all FRIDs except opioids. The interaction was consistently such that prescription indicated higher risk of falls in the gPop cohort than in the ID cohort.

Potential confounding of fall-risk-increasing disorders was assessed among those with prescription of FRIDs. In these cohort comparisons, adjusting for diagnosis of epilepsy lowered the crude RRs for FRIDs vs falls. When adjusting for diagnosis of epilepsy, the RR for falls among ID vs gPop was 1.07 (95% CI 0.97–1.18) for at least one FRID, 1.36 (1.16–1.61) for antidepressants, 1.13 (0.93–1.36) for anxiolytics, 1.42 (1.19–1.69) for hypnotics and sedatives, 2.18 (1.95–2.43) for opioids, and 0.89 (0.62–1.27) for antipsychotics. Adjusting for the other fall-risk-increasing disorders did not change the effect estimates more than marginally (all <10%; data not shown).

### Discussion

Older people with ID are more likely than their age peers in the general population to be prescribed FRIDs. They are also prescribed FRIDs at higher doses and for longer durations. Furthermore, people with ID that have been prescribed FRIDs are more likely than those in the general population to fall.

---

Table 1. Cohort comparison of prescription of fall risk-increasing drugs (FRIDs).

|                        | All (n = 7936) | Women (n = 3609) | Men (n = 4327) |
|------------------------|---------------|------------------|----------------|
| At least one FRID      | 2.31 (2.23–2.38) | 1.93 (1.85–2.02) | 2.78 (2.64–2.92) |
| Antidepressants        | 2.72 (2.55–2.91) | 2.23 (2.05–2.43) | 3.53 (3.18–3.91) |
| Anxiolytics            | 4.18 (3.90–4.49) | 3.33 (3.03–3.66) | 5.42 (4.86–6.05) |
| Hypnotics and sedatives| 1.42 (1.32–1.51) | 1.13 (1.03–1.24) | 1.84 (1.66–2.03) |
| Opioids                | 0.74 (0.69–0.79) | 0.76 (0.69–0.83) | 0.71 (0.64–0.78) |
| Antipsychotics (previously presented in [33]) | 25.0 (21.3–29.4) | NC | 27.8 (22.2–34.8) |

1 Numbers are given for each cohort.

2 Not calculated as the number of women in the gPop cohort with prescription was too low.

Risk ratios with 95% confidence intervals for prescription of fall risk-increasing drugs (FRIDs) for people with intellectual disability vs a one-to-one age and sex matched sample from the general population.

https://doi.org/10.1371/journal.pone.0199218.t001
### Table 2. Prescribed amount and number of years of prescription of fall-risk-increasing drugs during the study period (2006–2012).

| All | Women | Men |
|-----|-------|-----|
|     | DDD n Geometric mean (range) | Median (range) | Years | DDD n Geometric mean (range) | Median (range) | Years |
| At least one FRID | | | | | | |
| gPop | 4157 | 55 (1-3403) | 3 (1-7) | 2136 | 61 (1-2788) | 3 (1-7) | 2021 | 50 (1-3403) | 2 (1-7) |
| ID | 5787 | 164 (1-3121) | 7 (1-7) | 2707 | 160 (1-2642) | 7 (1-7) | 2021 | 168 (1-3121) | 7 (1-7) |
| ID vs gPop (p) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |

### Antidepressants

| gPop | 1523 | 160 (3-3052) | 3 (1-7) | 888 | 158 (3-1609) | 3 (1-7) | 635 | 163 (3-3052) | 2 (1-7) |
| ID | 2766 | 302 (0-3121) | 7 (1-7) | 1403 | 299 (2-1408) | 7 (1-7) | 1363 | 304 (0-3121) | 7 (1-7) |
| ID vs gPop (p) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |

### Anxiolytics

| gPop | 1331 | 25 (1-3900) | 2 (1-7) | 767 | 23 (1-1549) | 2 (1-7) | 564 | 28 (1-3900) | 1 (1-7) |
| ID | 3322 | 53 (1-2223) | 3 (1-7) | 1583 | 47 (1-2063) | 3 (1-7) | 1739 | 58 (1-2223) | 3 (1-7) |
| ID vs gPop (p) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |

### Hypnotics and sedatives

| gPop | 1823 | 86 (3-2524) | 3 (1-7) | 1030 | 86 (3-2500) | 3 (1-7) | 793 | 87 (5-2524) | 2 (1-7) |
| ID | 2201 | 147 (3-2642) | 4 (1-7) | 1036 | 145 (3-2642) | 4 (1-7) | 1165 | 149 (3-1931) | 4 (1-7) |
| ID vs gPop (p) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |

### Opioids

| gPop | 2761 | 20 (1-2788) | 1 (1-7) | 1356 | 20 (1-2788) | 1 (1-7) | 1405 | 19 (1-1057) | 1 (1-7) |
| ID | 2051 | 21 (1-2831) | 1 (1-7) | 1054 | 22 (1-1474) | 1 (1-7) | 997 | 20 (1-1057) | 1 (1-7) |
| ID vs gPop (p) | 0.038 | 0.96 | 0.081 | 0.90 | 0.27 | 0.63 | |

### Antipsychotics (previously presented in [33])

| gPop | 235 | 38 (1-1154) | 2 (1-7) | 116 | 31 (1-706) | 2 (1-7) | 119 | 47 (2-1154) | 2 (1-7) |
| ID | 3116 | 122 (1-2336) | 7 (1-7) | 1337 | 109 (1-1932) | 7 (1-7) | 1779 | 133 (1-2336) | 7 (1-7) |
| ID vs gPop (p) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |

1 DDDs are compared using Analysis of Variance (ANOVA) on ln-transformed values, and number of years are compared using the Mann-Whitney U-test.

Prescribed amount measured as Defined Daily Dose (DDD) and number of years with prescription of fall-risk-increasing drugs (FRIDs) during the study period among 7936 people with intellectual disability (ID) and a sample from the general population (gPop) one-to-one matched on sex and age.

### Table 3. Relative risks with 95% confidence intervals for falls.

| ID vs gPop | Prescription vs no prescription | Interaction p |
|------------|---------------------------------|---------------|
| All        | Prescription | No prescription | Prescription | gPop | p |
| At least one FRID | 1.27 (1.16–1.39) | 2.22 (1.98–2.49) | 2.27 (2.08–2.48) | 3.98 (3.56–4.44) | <0.001 |
| Antidepressants | 1.57 (1.33–1.86) | 2.20 (2.03–2.39) | 1.32 (1.21–1.44) | 1.85 (1.58–2.17) | <0.001 |
| Anxiolytics | 1.41 (1.17–1.69) | 2.14 (1.97–2.32) | 1.40 (1.28–1.52) | 2.11 (1.77–2.52) | <0.001 |
| Hypnotics and sedatives | 1.66 (1.40–1.97) | 2.29 (2.11–2.48) | 1.36 (1.24–1.50) | 1.88 (1.60–2.20) | 0.001 |
| Opioids | 2.43 (2.19–2.70) | 2.50 (2.24–2.68) | 6.36 (5.89–6.87) | 6.41 (5.76–7.13) | 0.91 |
| Antipsychotics | 1.00 (0.70–1.42) | 2.17 (2.00–2.35) | 1.11 (1.02–1.21) | 2.41 (1.70–3.42) | <0.001 |

Risk ratios with 95% confidence intervals for having at least one fall during the year for people with intellectual disability (ID) compared with a one-to-one age and sex matched sample from the general population (gPop) stratified by prescription of fall-risk-increasing drugs (FRIDs), and for having at least one prescription of FRIDs during the year stratified by cohort. p-values refer to interaction between cohort (ID or gPop) and prescription of each respective drug group.
People with ID were, with the exception of opioids, more likely than their age-peers in the general population to be prescribed all FRIDs that were analyzed in our study. They were also more likely to be prescribed higher doses and for a longer duration. In comparison with the general population, people with ID have higher occurrence of both somatic [10] and psychiatric [24, 34] diagnoses. Thus, that higher prescription rates should be found in this group is not surprising. However, the size of the increased frequency of prescriptions found in the present study does not correspond to the increased risk of psychiatric diagnoses found in the same population [24]. Hence, it cannot be ruled out that there is an over-prescription of FRIDs among older people with ID. Indeed, several studies have suggested that off-label prescriptions are common to treat challenging behaviors among people with ID [19, 35, 36]. This is worrisome as FRIDs have other adverse effects, not just an increased fall-risk, especially among older people [1, 37]. In Sweden, it is mandatory for health care providers to offer medication reviews to people aged 75+ years and with prescriptions of at least five drugs [38]. People with ID have been suggested to age at an earlier chronological stage [39]. Considering this, and that people with ID as a rule are prescribed more drugs and have higher disease burden than the general population, it would be prudent to start medication reviews even earlier in this population to ensure that all prescribed medications correspond to a correct and current indication. This is important for all medications, but for FRIDs in particular.

People with ID had an increased risk of falls compared with the general population. Somewhat surprisingly, this increase could not be explained by fall-risk increasing disorders prevalent among people with ID, other than epilepsy. Furthermore, even after adjusting for diagnosis of epilepsy, the fall-risk pattern was similar to the crude one, although slightly less pronounced. This highlights the complexity of falls and fall-risk factors among older people with ID. Nevertheless, among people with ID, as in the general population, falls may be prevented by exercises and physical activity [40, 41]. Thus, in addition to medication reviews, physiotherapy interventions are relevant among older people with ID in order to reduce falls.

In general, FRIDs implied a higher fall-risk among people in the general population than among people with ID. This is most likely not an indication of these drugs being less inappropriate among people with ID, but rather that the number of fall-risk factors are much higher in this population than among people without ID.

A major strength of the present study is the use of the Swedish Drug Prescription Register to obtain drug data. Starting July 2005, the register contains data concerning all purchases of prescribed drugs in Sweden [42]. All the FRIDs investigated in the present study are only sold via prescription in Sweden. Thus, no misclassification has been introduced by over-the-counter purchases. However, as only dispensed drugs are recorded, the information collected through the register is likely to be an underestimation of the number of prescriptions. Moreover, as purchase of a drug does not necessarily equal use (secondary non-adherence), register data is likely to be an overestimation of drug use. This needs to be considered in the interpretation of data.

In most populations, including the general Swedish population, the male-to-female ratio is generally in favor of women (i.e. below 1). However, in the present study, the opposite was found in the ID cohort (and consequently in the gPop cohort as well), i.e. there were fewer women than men. This raises the question of a possible skewness in the sex distribution in the present study. However, although declining with age, prevalence of ID is higher among men than women [43], resulting in a higher male-to-female ratio among people with ID than in the general population [44]. Thus, it should not be a cause of concern that the sex distribution in the ID cohort is skewed compared to the general population.

We used health care contacts in inpatient and outpatient specialist care, and registered as fall-related, as proxy for falls. This is, of course, an underestimation of all falls, as many falls
may not lead to any health care contact or to a visit in primary care. This is also something that needs to be taken into consideration when interpreting the results from the present study.

As only people alive at the end of 2012 were included in the study, falls severe enough to cause death are not included in the analyses. Thus, the number of falls found in the present study may be an underestimation of the true numbers. Moreover, if falls are more likely to cause death among people with ID than in the general population, the cohort comparisons will be biased. To the best of our knowledge, no studies have been performed comparing people with ID to the general population regarding death after falling. However, external underlying causes of death overall (i.e. including also poisoning, accidents, etc.) seem to be more common among people with ID [45, 46].

When analyzing the association between prescription of FRIDs and occurrence of falls, we did not take into account the timing of the prescription in relation to the fall. A contributing reason for this approach was that we had no data on when the FRID was used, only when it was purchased. Moreover, that we had information only on a relatively short time window (seven years), and we could not discriminate those who had not been prescribed FRIDs prior to this period from those who had. Thus, we can make no statements about a possible causality of prescription of FRIDs and risk of falls, but only draw conclusions about associations between these two factors.

In the general population sample, approximately one fourth were prescribed at least one FRID each year. This is in agreement with prescription rates in the whole of Sweden [47], suggesting that the gPop cohort constitutes a representative sample from the general population.

**Conclusions**

Older people with ID are more likely to be prescribed FRIDs and have a higher risk of falls requiring health care than their age-peers in the general population, even when taking into account differences in prevalence of fall-risk-increasing disorders. Moreover, they tend to have prescriptions for longer periods of time. Even without the use of FRIDs, older people with ID have a high risk of falls. It is important to be aware of this when prescribing drugs that increase the risk of falls further.

**Author Contributions**

**Conceptualization:** Anna Axmon, Magnus Sandberg, Gerd Ahlström, Patrik Midlöv.

**Data curation:** Anna Axmon.

**Formal analysis:** Anna Axmon.

**Funding acquisition:** Gerd Ahlström.

**Investigation:** Gerd Ahlström.

**Project administration:** Gerd Ahlström.

**Resources:** Gerd Ahlström.

**Software:** Anna Axmon.

**Supervision:** Gerd Ahlström.

**Validation:** Anna Axmon.

**Visualization:** Anna Axmon.

**Writing – original draft:** Anna Axmon.
References

1. National Board of Health and Welfare. Indicators of good drug therapy in the elderly [In Swedish: Indikatorer för god läkemedelsterapi hos äldre]. Swedish National Board of Health and Welfare (Socialstyrelsen), 2010.

2. Sterling DA, O’Connor JA, Bonadies J. Geriatric falls: Injury severity is high and disproportionate to mechanism. Journal of Trauma—Injury, Infection and Critical Care. 2001; 50(1):116–9.

3. Petropoulos E, Finlayson J, Hay M, Spencer W, Park R, Tannock H, et al. Injuries Reported and Recorded for Adults with Intellectual Disabilities Who Live with Paid Support in Scotland: a Comparison with Scottish Adults in the General Population. Journal of applied research in intellectual disabilities: JARID. 2016. doi: 10.1111/jar.12444 PMID: 26864714.

4. Finlayson J, Morrison J, Jackson A, Mantry D, Cooper SA. Injuries, falls and accidents among adults with intellectual disabilities. Prospective cohort study. J Intell Disabil Res. 2010; 54:966–80. doi: 10.1111/j.1365-2788.2010.01319.x PMID: 21040056.

5. Willgoss TG, Yohannes AM, Mitchell D. Review of risk factors and preventative strategies for fall-related injuries in people with intellectual disabilities. J Clin Nurs. 2010; 19(15–16):2100–9. doi: 10.1111/j.1365-2702.2009.03174.x PMID: 20569280.

6. Hsieh K, Herrer T, Miller AB. Risk factors for injuries and falls among adults with developmental disabilities. J Intell Disabil Res. 2001; 45:76–82. doi: 10.1046/j.1365-2788.2001.00277.x.

7. Cox CR, Clemenson L, Stancliffe RJ, Durvasula S, Sherrington C. Incidence of and risk factors for falls among older people with intellectual disabilities: fall rate, circumstances and consequences. J Intell Disabil Res. 2013; 57(12):1173–82. doi: 10.1111/j.1365-2788.2012.01643.x PMID: 23106830.

8. Smulders E, Enkelaar L, Weerdesteyn V, Geurts AC, van Schrojenstein Lantman-de Valk H. Falls in older persons with intellectual disabilities: fall rate, circumstances and consequences. J Intell Disabil Res. 2013; 57(12):1173–82. doi: 10.1111/j.1365-2788.2012.01643.x PMID: 23106830.

9. Sandberg M, Ahlström G, Kristensson J. Patterns of Somatic Diagnoses in Older People with Intellectual Disability: A Swedish Eleven Year Case-Control Study of Inpatient Data. Journal of applied research in intellectual disabilities: JARID. 2017; 30(1):157–71. doi: 10.1111/jar.12230 PMID: 26542759.

10. Hsieh K, Rimmer J, Heller T. Prevalence of Falls and Risk Factors in Adults with Intellectual Disability. J Appl Gerontol. 2012; 31(6):442–54. doi: 10.1177/0733464812451713.

11. Ambrose AF, Paul G, Hausdorff JM. Risk factors for falls among older adults: a review of the literature. Maturitas. 2013; 75(1):51–61. doi: 10.1016/j.maturitas.2013.02.009 PMID: 23823272.

12. Park H, Satoh H, Miki A, Urushihara H, Sawada Y. Medications associated with falls in older people: systematic review of publications from a recent 5-year period. Eur J Clin Pharmacol. 2015; 71(12):1429–40. doi: 10.1007/s00228-015-1955-3 PMID: 26407688.

13. Johnell K, Jonasdottir Bergman G, Fastbom J, Danielsson B, Borg N, Salmi P. Psychotropic drugs and the risk of fall injuries, hospitalisations and mortality among older adults. Int J Geriatr Psychiatry. 2016. doi: 10.1002/gps.4483 PMID: 27113813.

14. Ham AC, Swart KM, Enneman AW, van Dijk SC, Oliai Araghi S, van Wijngaarden JP, et al. Medication-related fall incidents in an older, ambulant population: the B-PROOF study. Drugs Aging. 2014; 31(12):917–27. doi: 10.1007/s40266-014-0225-x PMID: 25398701.

15. Bauer TK, Lindenbaum K, Stroka MA, Engel S, Linder R, Verheyen F. Fall risk increasing drugs and injuries of the frail elderly—evidence from administrative data. Pharmacoeconomics Drug Saf. 2012; 21(12):1321–7. doi: 10.1080/13596101.2012.692041.
Falls and fall-risk-increasing drugs among older people with intellectual disability

study. Aust N Z J Psychiatry. 2016; 50(4):352–62. Epub 2015/05/29. https://doi.org/10.1177/0048614515587951 PMID: 26019276.

19. Tsouris JA, Kim SY, Brown WT, Pettinger J, Cohen IL. Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord. 2013; 43(3):719–31. https://doi.org/10.1007/s10803-012-1617-6 PMID: 22829245.

20. Foran S, Dwyer MO, McCarron M, Henman M, McCallion P. Associations between medication use and falls among older adults with intellectual disability in Ireland. Age Ageing. 2016; 45:12-. WOS:000385109600053.

21. Guse CE, Porinsky R. Risk factors associated with hospitalization for unintentional falls: Wisconsin hospital discharge data for patients aged 65 and over. WMJ. 2003; 102(4):37–42. Epub 2003/09/12. PMID: 12967020.

22. Robertson J, Hatton C, Emerson E, Baines S. Prevalence of epilepsy among people with intellectual disabilities: A systematic review. Seizure. 2015; 29:46–62. Epub 2015/06/17. https://doi.org/10.1016/j.seizure.2015.03.016 PMID: 26076844.

23. Knight M, Coakley C. Fall risk in patients with acute psychosis. J Nurs Care Qual. 2010; 25(3):208–15. Epub 2010/02/06. https://doi.org/10.1177/1048731310361102 PMID: 2034336.

24. Axmon A, Björne P, Nylander L, Ahlström G. Psychiatric diagnoses in older people with intellectual disability in comparison with the general population: a register study. Epidemiol Psychiatr Sci. 2017;Feb 23:1–13. https://doi.org/10.1017/S2045796017000051 PMID: 28228177.

25. Sibley KM, Voth J, Munce SE, Straus SE, Jaglal SB. Chronic disease and falls in community-dwelling Canadians over 65 years old: a population-based study exploring associations with number and pattern of chronic conditions. BMC Geriatr. 2014; 14:22. Epub 2014/02/18. https://doi.org/10.1186/1471-2318-14-22 PMID: 24529293; PubMed Central PMCID: PMCPMC3928582.

26. Hermans H, Beekman AT, Evenhuis HM. Prevalence of depression and anxiety in older users of formal Dutch intellectual disability services. J Affect Disord. 2013; 144(1–2):94–100. Epub 2012/08/14. https://doi.org/10.1016/j.jad.2012.06.011 PMID: 22884239.

27. Stubbs B, Binnekade T, Eggermont L, Sephyry AA, Patchay S, Schofield P. Pain and the risk for falls in community-dwelling older adults: systematic review and meta-analysis. Arch Phys Med Rehabil. 2014; 95(1):175–87 e9. https://doi.org/10.1016/j.apmr.2013.08.241 PMID: 24036161.

28. Axmon A, Karlsson B, Ahlström G. Use of antipsychotics, benzodiazepine derivatives, and dementia medication among older people with intellectual disability and/or autism spectrum disorder and dementia. Res Dev Disabil. 2017; 62:50–7. https://doi.org/10.1016/j.ridd.2017.01.001 PMID: 28110116.

29. Scheifes A, Wairraven S, Stoker JJ, Nijman HL, Tenback DE, Egberts TC, et al. Movement Disorders in Adults With Intellectual Disability and Behavioral Problems Associated With Use of Antipsychotics. J Clin Psychopharmacol. 2016; 36(4):308–13. Epub 2016/06/15. https://doi.org/10.1097/JCP.0000000000000528 PMID: 27300250.

30. Balogh RS, Lake JK, Lin E, Wilton A, Lunskey Y. Disparities in diabetes prevalence and preventable hospitalizations in people with intellectual and developmental disability: a population-based study. Diabet Med. 2015; 32(2):235–42. https://doi.org/10.1111/dme.12573 PMID: 25185567.

31. Axmon A, Kristensson J, Ahlström G, Midløv P. Use of antipsychotics, benzodiazepine derivatives, and dementia medication among older people with intellectual disability and/or autism spectrum disorder and dementia. Res Dev Disabil. 2017; 62:50–7. https://doi.org/10.1016/j.ridd.2017.01.001 PMID: 28110116.

32. WHO. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2013.

33. Axmon A, Sandberg M, Ahlström G, Midløv P. Prescription of potentially inappropriate medications among older people with intellectual disability: a register study. BMC Pharmacol Toxicol. 2017; 18 (1):68. https://doi.org/10.1186/s40360-017-0174-1 PMID: 28907067; PubMed Central PMCID: PMCPMC5657112.

34. Deb S, Thomas M, Bright C. Mental disorder in adults with intellectual disability. I: Prevalence of functional psychiatric illness among a community-based population aged between 16 and 64 years. J Intellect Disabil Res. 2001; 45:495–505. WOS:000172484300003. PMID: 11737536

35. Doan TN, Lennox NG, Taylor-Gomez M, Ware RS. Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study. J Intellect Dev Disabil. 2013; 38 (2):177–81. https://doi.org/10.3109/13668250.2013.778968 PMID: 23550741.

36. Deb S, Unwin G, Deb T. Characteristics and the trajectory of psychotropic medication use in general and antispsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res. 2015; 59(1):11–25. https://doi.org/10.1111/jir.12119 PMID: 24450426.
37. American Geriatrics Society. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015; 63(11):2227–46. Epub 2015/10/09. https://doi.org/10.1111/jgs.13702 PMID: 26446832.

38. Socialstyrelsens föreskrifter och allmänna råd om läkemedelshantering i hälso- och sjukvården. (2001).

39. Haveman M, Heller T, Lee L, Maaskant M, Shooshtari S, Strydom A. Major Health Risks in Aging Persons With Intellectual Disabilities: An Overview of Recent Studies. J Policy Pract Intel. 2010; 7(1):59–69. doi: 10.1111/j.1741-1130.2010.00248.x. WOS:000283017700008.

40. Hale LA, Mirlin-Velitch BF, Treharne GJ. Prevention of falls for adults with intellectual disability (PRO-FAID): a feasibility study. Disabil Rehabil. 2016; 38(1):36–44. https://doi.org/10.3109/09638288.2015.1017613 PMID: 25714511.

41. Crockett J, Finlayson J, Skelton DA, Miller G. Promoting exercise as part of a physiotherapy-led falls pathway service for adults with intellectual disabilities: a service evaluation. Journal of applied research in intellectual disabilities: JARID. 2015; 28(3):257–64. Epub 2014/09/03. https://doi.org/10.1111/jar.12119 PMID: 25179503.

42. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007; 16(7):726–35. https://doi.org/10.1002/pds.1294 PMID: 16897791.

43. Westerinen H, Kaski M, Virta L, Almqvist F, Iivanainen M. Prevalence of intellectual disability: a comprehensive study based on national registers. J Intellect Disabil Res. 2007; 51(Pt 9):715–25. Epub 2007/09/12. https://doi.org/10.1111/j.1365-2788.2007.00970.x PMID: 17845240.

44. Lin J-D. Population with intellectual disability based on 2000–2007 national registers in Taiwan: Age and gender. Res Dev Disabil. 2009; 30(2):294–300. https://doi.org/10.1016/j.ridd.2008.05.001. https://doi.org/10.1016/j.ridd.2008.05.001 PMID: 18556173

45. O’Leary L, Cooper S-A, Hughes-McCormack L. Early death and causes of death of people with intellectual disabilities: A systematic review. Journal of Applied Research in Intellectual Disabilities.n/a-n/a. https://doi.org/10.1111/jar.12417 PMID: 28984406

46. Ng N, Flygare Wallen E, Ahlström G. Mortality patterns and risk among older men and women with intellectual disability: a Swedish national retrospective cohort study. BMC Geriatr. 2017; 17(1):269. Epub 2017/11/24. https://doi.org/10.1186/s12877-017-0665-3 PMID: 29166873; PubMed Central PMCID: PMCPMC5700486.

47. National Board of Health and Welfare. Statistikdatabas för läkemedel. Swedish National Board of Health and Welfare (Socialstyrelsen).